Scholarlink

<p>MicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression post-transcriptionally and play essential roles in proliferation, metabolism, stress responses, and apoptosis. Lung cancer (LC) remains one of the most common and lethal malignancies worldwide, with non-small cell lung cancer (NSCLC) accounting for about 80% of cases. Although advances in diagnosis and treatment have been made, clinical management is still challenged by drug resistance, metastasis, and treatment-related complications, and overall survival has only modestly improved. Accumulating evidence shows that dysregulated miRNA expression is closely linked to LC initiation and progression. miRNAs are involved in tumor growth, dissemination, and therapeutic responses, highlighting their potential as biomarkers for early detection, prognosis, and treatment prediction. Furthermore, strategies to modulate miRNA expression are emerging as promising therapeutic approaches. This review summarizes recent progress on miRNAs in LC, emphasizing their classification, interactions with signaling pathways, and translational potential in clinical applications, including diagnosis, prognosis, and therapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Research progress of MicroRNA in lung cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月29日

查看全文
  • Wenqing Long,
  • Lulin Cheng,
  • Yifan Shang,
  • Songqing Yu,
  • Min Zhang,
  • Huimin Du,
  • Yi Yue,
  • Zhiqi Zhang,
  • Chengfeng Xu,
  • Xinru Zhang,
  • Xiaoyi Liu,
  • Minghui Lu,
  • Bingfan Huang,
  • Lu Qiu,
  • Guozhong Jiang,
  • Zhibin Chen

摘要

MicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression post-transcriptionally and play essential roles in proliferation, metabolism, stress responses, and apoptosis. Lung cancer (LC) remains one of the most common and lethal malignancies worldwide, with non-small cell lung cancer (NSCLC) accounting for about 80% of cases. Although advances in diagnosis and treatment have been made, clinical management is still challenged by drug resistance, metastasis, and treatment-related complications, and overall survival has only modestly improved. Accumulating evidence shows that dysregulated miRNA expression is closely linked to LC initiation and progression. miRNAs are involved in tumor growth, dissemination, and therapeutic responses, highlighting their potential as biomarkers for early detection, prognosis, and treatment prediction. Furthermore, strategies to modulate miRNA expression are emerging as promising therapeutic approaches. This review summarizes recent progress on miRNAs in LC, emphasizing their classification, interactions with signaling pathways, and translational potential in clinical applications, including diagnosis, prognosis, and therapy.